Barclays PLC has notified Dechra Pharmaceuticals PLC of an increase in its voting rights. The notification, dated 17th January 2024, states that Barclays PLC's total positions now include 6.5% of voting rights attached to shares, up from the previous 5.91%. This increase was reported on 15th January 2024. The details of the shareholder, Barclays Capital Securities Limited, based in London, United Kingdom, were also provided in the notification.

The resulting situation on the date the threshold was crossed or reached indicates that Barclays PLC holds 6.02% of direct voting rights and 0.48% of indirect voting rights, totaling 6.5% of voting rights attached to shares, which amounts to 7,401,663 voting rights held in the issuer.

Barclays PLC's controlled undertakings, including Barclays Capital Securities Limited, effectively hold the voting rights and/or financial instruments. The full chain of controlled undertakings was outlined, starting with Barclays PLC as the ultimate controlling person, followed by Barclays Capital Securities Limited, which holds 6.02% of voting rights and 6.5% of voting rights through financial instruments.

The notification also included information about the financial instruments held by Barclays Capital Securities Limited, such as portfolio swaps, which account for 0.48% of voting rights. The completion date of the notification was 17th January 2024.

In summary, Barclays PLC has increased its voting rights in Dechra Pharmaceuticals PLC, with Barclays Capital Securities Limited now holding 6.5% of voting rights attached to shares, reflecting an acquisition of voting rights.